Foster Victor Wealth Advisors LLC Has $19.35 Million Stake in Boston Scientific Corporation $BSX

Foster Victor Wealth Advisors LLC boosted its holdings in Boston Scientific Corporation (NYSE:BSX) by 8.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 198,778 shares of the medical equipment provider’s stock after purchasing an additional 14,793 shares during the period. Boston Scientific comprises about 1.2% of Foster Victor Wealth Advisors LLC’s portfolio, making the stock its 23rd largest holding. Foster Victor Wealth Advisors LLC’s holdings in Boston Scientific were worth $19,345,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. FWL Investment Management LLC bought a new position in shares of Boston Scientific in the 2nd quarter valued at about $26,000. Sound Income Strategies LLC raised its holdings in Boston Scientific by 90.9% during the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 120 shares in the last quarter. Steph & Co. acquired a new position in Boston Scientific during the third quarter valued at approximately $25,000. 1248 Management LLC bought a new position in Boston Scientific in the first quarter valued at approximately $26,000. Finally, Kilter Group LLC acquired a new position in shares of Boston Scientific during the 2nd quarter worth approximately $30,000. 89.07% of the stock is owned by institutional investors.

Boston Scientific Stock Performance

NYSE BSX opened at $95.61 on Friday. The stock has a market cap of $141.74 billion, a PE ratio of 51.13, a P/E/G ratio of 1.93 and a beta of 0.67. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.96 and a current ratio of 1.51. The firm has a 50-day moving average of $98.64 and a 200-day moving average of $101.26. Boston Scientific Corporation has a 52-week low of $85.98 and a 52-week high of $109.50.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.71 by $0.04. The firm had revenue of $5.07 billion for the quarter, compared to analysts’ expectations of $4.97 billion. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. The business’s revenue was up 20.3% on a year-over-year basis. During the same period in the prior year, the firm earned $0.63 EPS. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. On average, sell-side analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current year.

Analyst Ratings Changes

BSX has been the subject of several analyst reports. Evercore ISI reissued an “outperform” rating on shares of Boston Scientific in a research note on Wednesday, October 22nd. Truist Financial cut their price target on shares of Boston Scientific from $130.00 to $120.00 and set a “buy” rating for the company in a research note on Thursday. Weiss Ratings restated a “buy (b-)” rating on shares of Boston Scientific in a research note on Wednesday, October 8th. Erste Group Bank downgraded shares of Boston Scientific from a “buy” rating to a “hold” rating in a research note on Friday, October 3rd. Finally, Leerink Partners lifted their price target on Boston Scientific from $127.00 to $128.00 and gave the stock an “outperform” rating in a report on Wednesday, October 1st. Two investment analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $124.85.

Insider Transactions at Boston Scientific

In related news, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the completion of the sale, the executive vice president directly owned 23,600 shares of the company’s stock, valued at approximately $2,396,580. This trade represents a 42.32% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the company’s stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $99.47, for a total value of $4,973,500.00. Following the completion of the transaction, the executive vice president directly owned 178,342 shares in the company, valued at approximately $17,739,678.74. This represents a 21.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 143,095 shares of company stock worth $14,228,950. Company insiders own 0.50% of the company’s stock.

Key Headlines Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: RBC Capital continues to rate BSX as an “outperform,” reinforcing buy-side support from a major bank and likely helping demand for shares. RBC Capital maintains Boston Scientific (BSX) outperform recommendation
• Positive Sentiment: Royal Bank of Canada analyst commentary suggests upside ahead for BSX, adding another institutional voice expecting price appreciation. This supports the bullish narrative among analysts. Boston Scientific (NYSE:BSX) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says
• Positive Sentiment: Truist reaffirmed a “buy” rating on BSX, signaling continued analyst confidence even as the firm updated its outlook—this helps underwrite medium-term investor sentiment. Truist Securities maintains Boston Scientific (BSX) buy recommendation
• Positive Sentiment: Zacks highlights BSX’s global expansion push — R&D, AI-driven manufacturing and a focused Emerging Markets effort targeting $1B+ revenue in China for 2025 — a strategic growth catalyst that supports longer-term upside. Boston Scientific’s Global Expansion: What’s Behind the Growth?
• Neutral Sentiment: Options flow is active around BSX; Benzinga’s options-focused piece notes positioning that can amplify intraday moves but doesn’t definitively indicate directional conviction from fundamental investors. Watch open interest and strike concentration for short-term signals. Decoding Boston Scientific’s Options Activity: What’s the Big Picture?
• Neutral Sentiment: Informational pieces recap BSX’s multi-year performance; useful for context but unlikely to move the stock today. These highlight solid historical returns that underpin investor confidence. Here’s How Much You Would Have Made Owning Boston Scientific Stock In The Last 5 Years
• Neutral Sentiment: Short-term market commentary notes BSX outperformed earlier sessions; useful for momentum traders but not a standalone fundamental driver. Boston Scientific (BSX) Advances While Market Declines
• Negative Sentiment: Truist cut its price target from $130 to $120 — a downward revision that may cap near-term upside and pressures sentiment despite the maintained “buy” rating. That target trim likely explains some of the selling pressure today. BSX price target lowered by Truist

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.